| 000 | 01070 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250515092756.0 | ||
| 264 | 0 | _c20071120 | |
| 008 | 200711s 0 0 eng d | ||
| 022 | _a1871-5265 | ||
| 024 | 7 |
_a10.2174/187152607781001817 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLaurenzi, M | |
| 245 | 0 | 0 |
_aChallenges associated with current and future TB treatment. _h[electronic resource] |
| 260 |
_bInfectious disorders drug targets _cJun 2007 |
||
| 300 |
_a105-19 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntitubercular Agents _xpharmacology |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMalate Synthase _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aTuberculosis _xdrug therapy |
| 700 | 1 | _aGinsberg, A | |
| 700 | 1 | _aSpigelman, M | |
| 773 | 0 |
_tInfectious disorders drug targets _gvol. 7 _gno. 2 _gp. 105-19 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/187152607781001817 _zAvailable from publisher's website |
| 999 |
_c17488905 _d17488905 |
||